Medical Innovation Exchange

GSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy

https://www.fiercebiotech.com/biotech/gsks-100m-adc-bet-doubt-after-fatality-first-trial-mersanas-therapy

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!